ReviewFrontiers in endocrinology2019
IL-33 at the Crossroads of Metabolic Disorders and Immunity.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Circulating interleukin-33 levels in obesity and type 2 diabetes: a systematic review and meta-analysis.American journal of physiology. Endocrinology and metabolism · 2024Pooled it
- IL-33/ST2 Signaling Sustains Hepato-Intestinal Homeostasis by Orchestrating Vascular Surveillance and Immune Regulatory Circuits During Experimental Trypanosoma cruzi Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- IL-33-induced neuroimmune regulation in depression: A narrative review from molecular mechanisms to therapeutic potential.Medicine · 2026Review
- Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents.Communications medicine · 2025Article
- Circulating Interleukins-33 and -37 and Their Associations with Metabolic Syndrome in Arab Adults.International journal of molecular sciences · 2024Article
- Critical and diverse role of alarmin cytokines in parasitic infections.Frontiers in cellular and infection microbiology · 2024Review
- Molecular and Metabolic Analysis of Arsenic-Exposed Humanized AS3MT Mice.Environmental health perspectives · 2023Article
- Knowledge mapping of interleukin-33: a bibliometric study.American journal of translational research · 2023Article
- Review
- IL-33 Participates in the Development of Esophageal Adenocarcinoma.Pathology oncology research : POR · 2022Article
- Dual role of interleukin-33 in tumors.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Circulating levels of IL-33 are elevated by obesity and positively correlated with metabolic disorders in Chinese adults.Journal of translational medicine · 2021Article
- Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment.Journal of translational medicine · 2020Article
- The Peripheral Immune System and Amyotrophic Lateral Sclerosis.Frontiers in neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a cytokine in interleukin-1(IL-1) family, interleukin-33(IL-33) usually exists in the cytoplasm and cell nucleus. When the cells are activated or damaged, IL-33 can be secreted into extracellular and regulate the functions of various immune cells through binding to its specific receptor suppression of tumorigenicity 2 (ST2). Except regulating the function of immune cells including T cells, B cells, dendritic cells (DCs), macrophages, mast cells, and innate lymphoid cells, IL-33 also plays an important role in metabolic diseases and has received an increasing attention. This review summarizes the regulation of IL-33 on different immune cells in lipid metabolism, which will help to understand the pathology of abnormal lipid metabolic diseases, such as atherosclerosis and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.